Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
1.310
-0.140 (-9.66%)
Oct 4, 2024, 4:00 PM EDT - Market closed
Verrica Pharmaceuticals Employees
Verrica Pharmaceuticals had 100 employees as of December 31, 2023. The number of employees increased by 78 or 354.55% compared to the previous year.
Employees
100
Change (1Y)
78
Growth (1Y)
354.55%
Revenue / Employee
$139,080
Profits / Employee
-$869,330
Market Cap
55.90M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Exagen | 179 |
HOOKIPA Pharma | 179 |
LENSAR | 130 |
Barinthus Biotherapeutics | 130 |
ProPhase Labs | 113 |
Aadi Bioscience | 89 |
BioLineRx | 79 |
Lucid Diagnostics | 70 |
VRCA News
- 3 days ago - Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - GlobeNewsWire
- 7 days ago - VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA - PRNewsWire
- 21 days ago - VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA - Business Wire
- 4 weeks ago - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York - GlobeNewsWire
- 7 weeks ago - Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 - GlobeNewsWire